133 related articles for article (PubMed ID: 22162573)
1. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.
Chi AS; Batchelor TT; Kwak EL; Clark JW; Wang DL; Wilner KD; Louis DN; Iafrate AJ
J Clin Oncol; 2012 Jan; 30(3):e30-3. PubMed ID: 22162573
[No Abstract] [Full Text] [Related]
2. Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.
Le Rhun E; Chamberlain MC; Zairi F; Delmaire C; Idbaih A; Renaud F; Maurage CA; Grégoire V
CNS Oncol; 2015; 4(6):381-6. PubMed ID: 26498130
[TBL] [Abstract][Full Text] [Related]
3. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
International Cancer Genome Consortium PedBrain Tumor Project
Nat Med; 2016 Nov; 22(11):1314-1320. PubMed ID: 27748748
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?
Gouji T; Takashi S; Mitsuhiro T; Yukito I
J Thorac Oncol; 2014 Mar; 9(3):e27-8. PubMed ID: 24518097
[No Abstract] [Full Text] [Related]
5. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
6. MET signaling pathway: a rational target for cancer therapy.
Appleman LJ
J Clin Oncol; 2011 Dec; 29(36):4837-8. PubMed ID: 22042966
[No Abstract] [Full Text] [Related]
7. Honokiol inhibits U87MG human glioblastoma cell invasion through endothelial cells by regulating membrane permeability and the epithelial-mesenchymal transition.
Joo YN; Eun SY; Park SW; Lee JH; Chang KC; Kim HJ
Int J Oncol; 2014 Jan; 44(1):187-94. PubMed ID: 24247297
[TBL] [Abstract][Full Text] [Related]
8. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
[TBL] [Abstract][Full Text] [Related]
9. Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas.
Yan B; Lim M; Zhou L; Kuick CH; Leong MY; Yong KJ; Aung L; Salto-Tellez M; Chang KT
J Clin Pathol; 2013 Nov; 66(11):985-91. PubMed ID: 23801497
[TBL] [Abstract][Full Text] [Related]
10. Response to Selpercatinib in a Patient With Recurrent Glioblastoma and RET Amplification.
Czech C; Chen A; Morgan KP; Zamora C; El-Refai S; Poynter N; Khagi S
J Natl Compr Canc Netw; 2022 Sep; 20(9):966-971. PubMed ID: 36075388
[TBL] [Abstract][Full Text] [Related]
11. Osthole inhibits insulin-like growth factor-1-induced epithelial to mesenchymal transition via the inhibition of PI3K/Akt signaling pathway in human brain cancer cells.
Lin YC; Lin JC; Hung CM; Chen Y; Liu LC; Chang TC; Kao JY; Ho CT; Way TD
J Agric Food Chem; 2014 Jun; 62(22):5061-71. PubMed ID: 24828835
[TBL] [Abstract][Full Text] [Related]
12. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
Ou SH; Bazhenova L; Camidge DR; Solomon BJ; Herman J; Kain T; Bang YJ; Kwak EL; Shaw AT; Salgia R; Maki RG; Clark JW; Wilner KD; Iafrate AJ
J Thorac Oncol; 2010 Dec; 5(12):2044-6. PubMed ID: 21102269
[No Abstract] [Full Text] [Related]
13. The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target.
Boccaccio C; Comoglio PM
Cancer Res; 2013 Jun; 73(11):3193-9. PubMed ID: 23695554
[TBL] [Abstract][Full Text] [Related]
14. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
Snuderl M; Fazlollahi L; Le LP; Nitta M; Zhelyazkova BH; Davidson CJ; Akhavanfard S; Cahill DP; Aldape KD; Betensky RA; Louis DN; Iafrate AJ
Cancer Cell; 2011 Dec; 20(6):810-7. PubMed ID: 22137795
[TBL] [Abstract][Full Text] [Related]
15. MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma.
Burel-Vandenbos F; Ngo-Mai M; Dadone B; Di Mauro I; Gimet S; Saada-Bouzid E; Bourg V; Almairac F; Fontaine D; Virolle T; Pedeutour F
Neuropathol Appl Neurobiol; 2017 Apr; 43(3):252-266. PubMed ID: 26946354
[TBL] [Abstract][Full Text] [Related]
16. High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
Feng Y; Minca EC; Lanigan C; Liu A; Zhang W; Yin L; Pennell NA; Farver C; Tubbs R; Ma PC
J Thorac Oncol; 2014 May; 9(5):646-53. PubMed ID: 24722154
[TBL] [Abstract][Full Text] [Related]
17. Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics.
Byeon SJ; Cho HJ; Baek HW; Park CK; Choi SH; Kim SH; Kim HK; Park SH
Hum Pathol; 2014 Mar; 45(3):611-20. PubMed ID: 24457079
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas.
Kubelt C; Hattermann K; Sebens S; Mehdorn HM; Held-Feindt J
Int J Oncol; 2015; 46(6):2515-25. PubMed ID: 25845427
[TBL] [Abstract][Full Text] [Related]
19. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
20. Clinical and radiographic stabilization of intracranial glioblastoma. Report of a case treated after surgery with tamoxifen.
Mastronardi L; Farah JO; Puzzilli F; Qasho R; Lunardi P
J Neurosurg Sci; 1996 Jun; 40(2):129-33. PubMed ID: 9049896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
